Chen Xu-Zheng, Cao Zhi-Yun, Zhang You-Quan, Li Jin-Nong, Liao Lian-Ming, Du Jian
Center of Oncology, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China.
Department of Clinical Laboratory, The Second Affiliated Hospital, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350003, P.R. China.
Oncol Lett. 2017 May;13(5):3261-3268. doi: 10.3892/ol.2017.5849. Epub 2017 Mar 13.
Fuzheng Qingjie (FZQJ) is a polyherbal Chinese medicine that has previously been implemented as an adjuvant therapy for gastrointestinal cancer. The present study investigated whether FZQJ is able to potentiate the anticancer effect of cyclophosphamide (CTX). Hepatoma 22 tumor-bearing mice were randomly divided into a vehicle group, CTX group, FZQJ group and combination (CTX+FZQJ) group. In addition, untreated mice without H22 cells served as blank controls. Seven days post-treatment, the mice were sacrificed and the tumors were weighed. Blood cells were evaluated using an automatic hemocytometer analyzer and flow cytometer. The expression levels of interleukin (IL)-2 and tumor necrosis factor (TNF)-α were evaluated using a radioimmunoassay. Apoptotic cells were observed using a terminal deoxynucleotidyl transferase dUTP nick-end labeling assay. Alanine transaminase, aspartate aminotransferase, blood urea nitrogen and creatinine were examined using an automatic biochemical analyzer. The results demonstrated that the tumor inhibitory rate and apoptosis index were higher in the combination group, compared with those in the CTX group. Notably, FZQJ was able to alleviate CTX-induced decreases in the numbers of white blood cells and platelets, CD3 and CD4 T lymphocyte subsets, and the concentration of hemoglobin, body weight and thymus index, and increase serum TNF-α and IL-2 levels without overt hepatorenal toxicity. These results suggest that FZQJ granules may enhance the anticancer effect of CTX, in addition to alleviating the side effects.
扶正清解(FZQJ)是一种多味中药复方,此前已被用作胃肠道癌的辅助治疗药物。本研究调查了FZQJ是否能够增强环磷酰胺(CTX)的抗癌效果。将荷肝癌22的小鼠随机分为溶剂对照组、CTX组、FZQJ组和联合用药(CTX+FZQJ)组。此外,未接种H22细胞的未处理小鼠作为空白对照。治疗7天后,处死小鼠并对肿瘤称重。使用自动血细胞分析仪和流式细胞仪评估血细胞。使用放射免疫分析法评估白细胞介素(IL)-2和肿瘤坏死因子(TNF)-α的表达水平。使用末端脱氧核苷酸转移酶dUTP缺口末端标记法观察凋亡细胞。使用自动生化分析仪检测丙氨酸转氨酶、天冬氨酸转氨酶、血尿素氮和肌酐。结果表明,联合用药组的肿瘤抑制率和凋亡指数高于CTX组。值得注意的是,FZQJ能够减轻CTX诱导的白细胞和血小板数量、CD3和CD4 T淋巴细胞亚群以及血红蛋白浓度、体重和胸腺指数的降低,并提高血清TNF-α和IL-2水平,且无明显肝肾毒性。这些结果表明,FZQJ颗粒除了减轻副作用外,还可能增强CTX的抗癌效果。